Continuing Medical Education Program – Purchase Activities

The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for healthcare professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs and changes in therapeutics. The objectives of the program are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter CME Program is funded by fees paid by the activity participants. The Medical Letter is free of commercial influence and financial sponsorship.

The Medical Letter Individual Activities — Online Only

I would like to order the following Per Issue Activities eligible for 2 credits each:

$15 per activity
3 or more: $10/activity

	1675 (2 credits) Expires 04/18/2024 Vibrant - An Oral Vibrating Capsule for Chronic Idiopathic Constipation Altuviiio - A Longer-Acting Factor VIII Product for Hemophilia A Lenacapavir (Sunlenca) for Multidrug-Resistant HIV Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis

	1676 (2 credits) Expires 05/02/2024 Choice of Contraceptives

	1677 (2 credits) Expires 05/16/2024 Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia Cariprazine (Vraylar) for Adjunctive Treatment of Depression

	1678 (2 credits) Drugs for Migraine

	1679 (2 credits) Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia Expanded Heart Failure Indication for Dapagliflozin (Farxiga) Alternatives to Mifepristone for Medication Abortion OTC Ivermectin for Head Lice

	1680 (2 credits) Drugs for Inflammatory Bowel Disease

	1681 (2 credits) Tofersen (Qalsody) for ALS Sotagliflozin (Inpefa) for Heart Failure Zavegepant (Zavzpret) for Acute Treatment of Migraine Inspire for Obstructive Sleep Apnea

	1682 (2 credits) Drugs for Anxiety Disorders

	1683 (2 credits) Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease Bexagliflozin (Brenzavvy) - A Fifth SGLT2 Inhibitor for Type 2 Diabetes Once-Weekly or Once-Monthly SC Buprenorphine (Brixadi) for Opioid Use Disorder Linaclotide (Linzess) for Functional Constipation

	1684 (2 credits) Drugs for Opioid Use Disorder

	1685 (2 credits) Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children Suflave - A Low-Volume Colonoscopy Preparation Opill - An OTC Oral Contraceptive

	1686 (2 credits) Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention Valoctocogene Roxaparvovec (Roctavian) - A Gene Therapy for Severe Hemophilia Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy

	1687 (2 credits) Influenza Vaccine for 2023-2024 Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose

	1688 (2 credits) Drugs for Gout AD-Detect - A Blood Test for Alzheimer's Disease

	1689 (2 credits) Antiviral Drugs for Influenza for 2023-2024 New Novavax Vaccine Formulation for 2023-2024 Empagliflozin (Jardiance) for Chronic Kidney Disease

	1690 (2 credits) Ritlecitinib (Litfulo) for Severe Alopecia Areata Etrasimod (Velsipity) for Ulcerative Colitis Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia Shockwave Therapy for Erectile Dysfunction

	1691 (2 credits) Drugs for Depression

	1692 (2 credits) Zuranolone (Zurzuvae) - An Oral Drug for Postpartum Depression Vonoprazan (Voquezna) for Erosive Esophagitis Tirzepatide (Zepbound) for Chronic Weight Management Three New Injectable Antipsychotic Drugs

	1693 (2 credits) Treatment of Atrial Fibrillation

	1694 (2 credits) Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease Bimekizumab (Bimzelx) for Psoriasis Perfluorohexyloctane Ophthalmic Solution (Miebo) for Dry Eye Disease Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration

	1695 (2 credits) Drugs for Acne Drugs for Rosacea IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure

	1696 (2 credits) Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum Rozanolixizumab (Rystiggo) for Myasthenia Gravis Balfaxar: Another Four-Factor PCC for Warfarin Reversal

	1697 (2 credits) Drugs for Menopausal Symptoms Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease Severe Hypocalcemia with Denosumab (Prolia) in Chronic Kidney Disease

	1698 (2 credits) Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma Penbraya: A Pentavalent Meningococcal Vaccine Mirikizumab (Omvoh) for Ulcerative Colitis A New OTC Naloxone Nasal Spray (RiVive)

	1699 (2 credits) Drugs for Bipolar Disorder Omalizumab (Xolair) for Food Allergy

	1700 (2 credits) Roflumilast Foam (Zoryve) for Seborrheic Dermatitis Cabtreo: A Three-Drug Gel for Acne Zilucoplan (Zilbrysq) for Myasthenia Gravis Donislecel (Lantidra) for Type 1 Diabetes

	1701 (2 credits) Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis A New Indication for Semaglutide (Wegovy) Intravenous Acetaminophen/Ibuprofen (Combogesic IV) iDose TR - A Travoprost Implant for Glaucoma Antibiotic Prophylaxis for Dental Procedures

Add to Cart

ACCME The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)^TM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Your participation information will be shared with ABIM through PARS.

ABS CC Successful completion of this CME activity enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

AAFP The AAFP has reviewed The Medical Letter Continuing Medical Education Program, and deemed it acceptable for AAFP credit. Term of approval is from 01/01/2024 to 12/31/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

Accreditation Council on Pharmacy Education
The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each exam is acceptable for 2.0 hours of knowledge-based continuing education credit (0.2 CEU).